CD274 and breast carcinoma: Although clinical trials for immunotherapy in breast cancer have not shown that same high efficacy as in other carcinomas, TNBC is likely to have increased benefit as compared to other types of breast cancer given high mutational load, DDR-deficiency and increased PD-L1 expression.